SEC11B: A Potential Drug Target and Biomarker (G157708)

Target Name: SEC11B

NCBI ID: G157708

SEC11B

Other Name(s): SEC11 homolog B, signal peptidase complex subunit (pseudogene) | SEC11L2 | SPCS4B | SEC11 homolog B, pseudogene (S. cerevisiae)

SEC11B: A Potential Drug Target and Biomarker

SEC11B (Sec11 homolog B, signal peptidase complex subunit) is a protein that is expressed in various cell types, including bacteria, archaea, and eukaryotes. It is a part of the signal peptidase complex, which is a protein-protein interaction module that plays a crucial role in the delivery of proteins to their target cells. SEC11B is a 21-kDa protein that consists of two distinct domains: a N-terminal alpha-helices domain and a C-terminal T-loop domain.

The N-terminal domain of SEC11B contains a heptadecapeptide that is known as the signal peptide. This peptide is composed of 11 amino acids and is the portion of the protein that is involved in the recognition of specific peptides by the signal peptidase. The C-terminal domain of SEC11B contains a single amino acid residue (G201) that is part of a T-loop that is involved in the formation of the protein structure.

SEC11B is expressed in various cell types and is involved in the delivery of proteins to the endoplasmic reticulum (ER) and other intracellular structures. It has been shown to play a role in the delivery of proteins to the ER, including the delivery of proteins involved in cell signaling pathways, such as neurotransmitter receptors. In addition, SEC11B has also been shown to be involved in the delivery of proteins involved in cell adhesion and migration, such as cadherins and vimentin.

SEC11B has also been shown to be involved in the regulation of cellular processes, including cell growth, apoptosis, and inflammation. For example, studies have shown that SEC11B is involved in the regulation of cell cycle progression, and that it plays a role in the delivery of proteins involved in cell cycle regulation, such as cyclin D1. In addition, SEC11B has also been shown to be involved in the regulation of cell apoptosis, and that it plays a role in the delivery of proteins involved in apoptosis, such as Bcl-2.

In addition to its role in cell regulation, SEC11B has also been shown to be involved in the delivery of proteins involved in protein-protein interactions, such as the delivery of proteins involved in the delivery of small molecules to the endoplasmic reticulum.

Given the various roles that SEC11B has been shown to play in cellular processes, it is a potential drug target. Studies have shown that SEC11B can be inhibited by small molecules, and that this inhibition can have a variety of cellular effects, including the inhibition of cell growth, the inhibition of cell apoptosis, and the inhibition of protein-protein interactions.

In addition, SEC11B has also been shown to be involved in the regulation of cellular signaling pathways, and studies have shown that it can interact with a variety of signaling proteins, including TGF-β1, NF-kappa-B, and MAPK. This suggests that SEC11B may be a useful biomarker for the treatment of diseases associated with these signaling pathways, such as cancer and neurodegenerative diseases.

In conclusion, SEC11B is a protein that is involved in various cellular processes, including cell regulation and protein-protein interactions. It is a potential drug target and biomarker, and its study may provide new insights into the mechanisms of cellular regulation and disease. Further research is needed to fully understand the role of SEC11B in cellular processes and its potential as a drug target.

Protein Name: SEC11 Homolog B, Signal Peptidase Complex Subunit (pseudogene)

Functions: Putative component of some signal peptidase complex which removes signal peptides from nascent proteins as they are translocated into the lumen of the endoplasmic reticulum

The "SEC11B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEC11B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets